M6P Therapeutics Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today a poster presentation on mucolipidosis type II at the American Society of Gene & Cell Therapy’s (ASGCT) 24^th Annual Meeting: May 11-14, 2021.

The details of the virtual presentation are as follows:

• Abstract Title: “Pilot Study of M002, a Novel AAV9-Mediated Gene Therapy for Treatment of Mucolipidosis Type II (MLII) Using a Modified Phosphotransferase (S1S3)”
• Session Date/Time: Tuesday May 11, 2021 8:00 - 10:00 a.m. ET
• Session Title: AAV Vectors - Preclinical and Proof-of-Concept Studies
• Room: Digital Gallery
• Final abstract number: 373

About M6P Therapeutics

M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics’ proprietary bicistronic-S1S3 platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics’ team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of recombinant enzyme and gene therapies by harnessing the power of protein phosphorylation using its bicistronic-S1S3 platform. M6P Therapeutics’ mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: www.m6ptherapeutics.com.